MiNK Therapeutics

Contributing Author

Recent Articles by MiNK Therapeutics

Apr-03	MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 INKT GlobeNewswire
Apr-02	MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy INKT GlobeNewswire
Apr-01	MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference INKT GlobeNewswire
Mar-31	MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum INKT GlobeNewswire
Mar-17	MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs INKT GlobeNewswire
Mar-10	MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers INKT +29.28% GlobeNewswire
Feb-03	MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia INKT GlobeNewswire
Jan-08	MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease INKT GlobeNewswire
Nov-20	MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors INKT GlobeNewswire
Nov-14	MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation INKT GlobeNewswire
Nov-07	MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 INKT GlobeNewswire
Nov-05	MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development INKT GlobeNewswire
Oct-30	MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting INKT GlobeNewswire
Sep-29	MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors INKT GlobeNewswire
Sep-25	MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA INKT -5.09% GlobeNewswire
Sep-18	MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development INKT +7.79% GlobeNewswire
Aug-14	MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results INKT -12.46% GlobeNewswire
Jul-31	MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report INKT -8.34% GlobeNewswire
Jul-15	MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy INKT -31.03% GlobeNewswire
Jul-11	MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer INKT +730.14% GlobeNewswire
Jun-10	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting INKT +5.84% GlobeNewswire
Jun-02	MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients INKT GlobeNewswire
May-15	MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress INKT GlobeNewswire
May-05	MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report INKT GlobeNewswire

MiNK Therapeutics

Recent Articles by MiNK Therapeutics

Upgrade your Finviz experience